Novartis's Targeted Radioligand Improves OS And PFS In Prostate Cancer
Further Details At Upcoming Medical Meeting
Novartis’s PSMA-targeted radioligand has improved overall survival and progression-free survival in top-line results from the Phase III VISION study in prostate cancer, cementing the company's pioneering role in the therapeutic area.
